March 13, 2019 Scholar thinks Glaxo made a wise move to back Merck Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
July 02, 2018 June rush drives near-record quarter for biotech flotations Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.
